Analyst Conference Summary |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Biotechnology
|
Regeneron Pharmaceuticals
|
therapy | Q4 2024 | Q3 2024 | Q4 2023 | y/y |
Eylea | $ | $1,145 | $ | % |
Eylea HD | 392 | |||
Praluent* | 53 | % | ||
Evkeeza | 32 | % | ||
Inmazeb | 35 | na | ||
Libtayo | 289 | % | ||
*global sales, including by partners
Non-GAAP results: net income $ billion, up % sequentially from $1.46 billion and up % from $ billion year earlier. Diluted EPS $, up % sequentially from $12.46 and up % from $ year-earlier.
See also the Regeneron Pipeline.
Cash and equivalents balance ended at $ billion, up sequentially from $18.3 billion. $ billion long-term debt. Cash from operations was $ billion, free cash flow $ billion. $ million was used for shares repurchased in the quarter.
GAAP expenses of $ billion consisted of: cost of goods sold $ million; research and development $ billion; acquired in-process R&D $ million; selling, general and administrative $ million; collaboration manufacturing costs $ million; other operating expense $ million. Leaving income from operations of $ billion. Other income was $ million. Income tax $ million.
Q&A selective summary:
OpenIcon Analyst Conference Summaries Main Page
More Analyst Conference Pages:
AGEN |
AGIO |
ALLO |
ALNY |
AMAT |
AMGN |
APRE |
ARWR |
BIIB |
BLRX |
BLUE |
BMY |
CLDX |
CDTX |
FATE |
GILD |
GLYC |
ILMN |
INCY |
INO |
IONS |
MCHP |
MRNA |
PLX |
REGN |
RNA |
SAGE |
SANA |
SYRS |
TSVT |
VRTX |
VSTM |
WBA |
Disclaimer: My analyst call summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. These are my personal notes and serve as the basis of my Seeking Alpha articles.
Copyright 2025 William P. Meyers